Abstract
Febuxostat is a novel, nonpurine, selective xanthine oxidase inhibitor and is a potential alternative to allopurinol for patients with hyperuricemia and gout. Unlike allopurinol, which undergoes renal elimination, febuxostat is metabolized via hepatic conjugation and oxidation. Phase III studies have shown that febuxostat, at a once-daily dose of 80, 120 or 240 mg (safety dose), is more effective than allopurinol (300 mg) in reducing and maintaining serum urate concentrations lower than 6 mg/dl. Reductions in gout flares and tophus areas with febuxostat treatment are similar to those occurring with allopurinol therapy. Patients with moderate renal impairment can achieve significant serum urate reductions, without dose adjustments. Therefore, febuxostat represents a viable treatment choice, with documented efficacy and safety in hyperuricemia and gout.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
